Study: Avastin, docetaxel combo stalls breast cancer progression

02/12/2008 | NYTimes.com · TheStreet.com

A study involving 736 women found that the combination of Genentech's cancer drug Avastin and docetaxel chemotherapy extended progression-free survival in breast cancer patients who have not undergone chemotherapy. The new study, sponsored by Genentech shareholder Roche Holding, may shore up the drug's chances for FDA approval as a breast cancer drug.

View Full Article in:

NYTimes.com · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA